Acute Leukemia

An Illustrated Guide to Diagnosis and Treatment
Herausgeber: Emadi, Ashkan; Karp, Judith E

• Gebundenes Buch

Produktbeschreibung

Provides a comprehensive and concise visual reference on acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) seen in children and adults. This book addresses all aspects of AML and ALL including their risk factors, cytogenetics and mutational characteristics, diagnoses, clinical management and prognoses. It presents complex information relying predominantly on pictorial depictions.

Produktdetails

• Verlag: Springer Publishing Company
• Seitenzahl: 376
• Erscheinungstermin: 17. Juli 2017
• Englisch
• Abmessung: 254mm x 218mm x 23mm
• Gewicht: 1043g
• ISBN-13: 9781620701003
• ISBN-10: 1620701006
• Artikelnr.: 47173073

Autorenporträt

Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.

Inhaltsangabe

Contents
Contributors
Abbreviations
Preface
1. Epidemiology
Ashkan Emadi, Farin Kamangar, and Judith E. Karp
2. Diagnosis
Clinical Manifestations of Acute Leukemia
Daniel L. Duncan, Nathan D. Montgomery, Matthew C. Foster, and Joshua F.
Zeidner
Pathology, Classification, and Methodologies
Histopathology
Zeba N. Singh and Qing C. Chen
Classification of AML
Zeba N. Singh and Qing C. Chen
Classification of ALL
Zeba N. Singh and Qing C. Chen
Classical Genetics
Ying Zou and Yi Ning
Modern Molecular Genetics
Parvez M. Lokhandwala and Christopher D. Gocke
Molecular Mutations in AML
Catherine Lai
FLT3
Mark J. Levis
C-KIT
Joshua F. Zeidner
Ras/Raf/MEK/ERK Pathways
Frank McCormick
NPM1
Alexander E. Perl
PI3K/AKT/mTOR Pathway
Mohamed Rahmani and Steven Grant
RUNX1
Chandrima Sinha, Lea C. Cunningham, and Paul P. Liu
MLL
Peter D. Aplan
CEBPa
Alan D. Friedman
GATA2
Dennis D. Hickstein
DNMT3A
Timothy J. Ley and David H. Spencer
TET and IDH
Amir T. Fathi
WT1
Sheenu Sheela, John Barrett, and Catherine Lai
ASXL1 and EZH2
Lizamarie Bachier-Rodriguez and Joseph M. Scandura
EVI1
Ling Li and Guido Marcucci
p53
Sami N. Malek
Secondary AML (s-AML)
R. Coleman Lindsley
MicroRNAs: Networks in Acute Leukemia
Lukasz P. Gondek and Gabriel Ghiaur
Prognostic Implication of Mutational Interplay
Ashkan Emadi and Judith E. Karp
Molecular Mutations in ALL
Kristen O'Dwyer and Anjali Advani
3. Therapy
Management of Early Crisis
Hyperleukocytosis
Heather J. Male and Tara Lin
Tumor Lysis and Cytokine Release Syndromes
Ashkan Emadi and Judith E. Karp
Febrile Neutropenia
Judith E. Karp
Treatment of AML in Adults
AML Treatment in Younger Patients
Joshua F. Zeidner and Matthew C. Foster
AML Treatment in Older Patients
Houman Nourkeyhani and Eunice S. Wang
Treatment of Relapsed/Refractory AML
Mark R. Litzow and Selina M. Luger
Acute Promyelocytic Leukemia (APL)
Aziz Nazha, Steven D. Gore, and Amer Methqal Zeidan
MDS/AML
Fundamentals of Epigenetics
Monica Reddy Muppidi, Priyank P. Patel, Adam R. Karpf, and Elizabeth A.
Griffiths
Clonal Evolution and Treatment of Secondary AML and MDS/AML
Vu H. Duong and Amer Methqal Zeidan
Treatment of ALL in Adults
Matthew J. Wieduwilt
Risk Stratification
General Therapeutic Principles
Relapsed/Refractory ALL
Conclusion
Treatment of AML in Children/Adolescents
Jessica Knight-Perry and Lia Gore
De Novo AML
APML
AML With Trisomy 21
Relapsed/Refractory AML
Common Complications and Supportive Care
Indication for Allogeneic Stem Cell Transplant
Adolescent and Young Adult (AYA) Patients With Acute Lymphoblastic Leukemia
(ALL) and Lymphoblastic Lymphoma: Epidemiology, Survival Trends, and
Optimal Therapy
Archie Bleyer
Treatment of ALL in Children and Adolescents
Susan R. Rheingold and Stephen P. Hunger
Prognostic Indicators/Risk Stratification
ALL Therapy
Radiation Therapy
Outcome
Infant ALL
Down Syndrome-Associated ALL
Philadelphia Chromosome Positive (Ph+) and Philadelphia Chromosome-Like ALL
Targeted Therapies
Relapsed/Refractory ALL
Indications for Allogeneic Stem Cell Transplant
4. Allogeneic Transplant in Adults and Children for AML and ALL
Allen R. Chen, Gordon Cohen, Sawa Ito, Heather Symons, and Nancy M. Hardy
5. Measurable (Minimal) Residual Disease
The Mechanics of Quantized Hematopoiesis
Michael R. Loken
Fundamentals of Quantitative Antigen Expression
Maturation in Hematopoiesis is Characterized by Quantized Steps
Neoplastic Transformation Results in Disruption of Maturation
Summary
Minimal Residual Disease (MRD) in Acute Lymphoblastic Leukemia (ALL): An
Important Prognostic Indicator and Efficacy/Response Biomarker in Children
and Adults
Gregory H. Reaman and Franklin O. Smith III
Clinical Significance of MRD Detection
Role of MRD as a Drug Development Tool in ALL
Sequence-Specific MRD for ALL
Aaron C. Logan
Measurable Residual Disease for AML
Christopher S. Hourigan and Aaron C. Logan
6. Psychosexual Aspects of Management of Acute Leukemia
Nancy Corbitt and Trisha Kendall
7. Chemotherapeutic Agents for Treatment of AML and ALL
Ashkan Emadi, Noa G. Holtzman, Matthew J. Wieduwilt, and Judith E. Karp
8. New Therapeutic Targets for Acute Leukemia
Stem Cells
Craig T. Jordan and Daniel A. Pollyea
Exploiting the DNA Damage Response and Repair Pathways
Ivana Gojo, Keith W. Pratz, and Judith E. Karp
Poly(ADP-Ribose) Polymerase (PARP): An Intriguing Molecular Target for
Leukemia
Targeting Tumor Metabolism for Treatment of Acute Leukemia
Firas El Chaer and Ashkan Emadi
Mechanisms of Drug Resistance in Acute Leukemia
Maria R. Baer
Microenvironment
Gabriel Ghiaur and Pamela S. Becker
Immunology
Hanna A. Knaus, Raúl Montiel Esparza, and Ivana Gojo
9. Regulatory Considerations for the Practitioner
Donna Przepiorka and Ann T. Farrell
Index